XML 55 R44.htm IDEA: XBRL DOCUMENT v3.26.1
Business Combination - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 12, 2026
Feb. 12, 2026
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Business Combination [Line Items]                  
Ordinary shares, par value (in dollars per share)     $ 0.01       $ 0.01   $ 0.01
Recognized share-based compensation expense $ 18,400,000           $ 400,000    
Total revenues     $ 496,009,000   $ 390,657,000   888,920,000 $ 697,167,000  
Net Income (Loss)     501,000 $ (66,480,000) $ 87,098,000 $ 22,464,000 (65,979,000) $ 109,562,000  
Avadel Pharmaceuticals Plc                  
Business Combination [Line Items]                  
Issued ordinary share $ 21 $ 21              
Ordinary shares, par value (in dollars per share) 0.01 0.01              
Potential additional cash payment per share upon achievement of certain specific milestone $ 1.5 $ 1.5              
Contingent payments $ 165,700,000 $ 165,700,000 165,700,000       165,700,000    
Contingent consideration liability 107,700,000 107,700,000              
Purchase price 134,900,000                
Recognized share-based compensation expense 1,800,000                
Total revenues     96,600,000       136,100,000    
Net Income (Loss)     (2,700,000)       13,600,000    
Deferred tax liability 183,129,000 183,129,000 183,100,000       183,100,000    
Deferred tax assets 849,000 849,000 800,000       800,000    
Uncertain tax position in connection with U.S. state tax position 2,200,000 2,200,000              
Adjustments to reduce deferred tax asset 400,000 400,000              
Adjustments in reduction of estimated value of goodwill 1,800 1,800              
Transaction costs     1,100,000       1,100,000    
Acquisition related costs     35,900,000       35,900,000    
Direct one-time transaction costs   $ 64,600,000 $ 77,700,000       $ 77,700,000    
Direct one-time acquisition transaction costs 45,600,000               $ 9,700,000
Acceleration of unvested share-based compensation awards $ 20,200,000